Collectively, specific FOXOs may differentially contribute to DLBCL disease progression, with FOXO1 and FOXO3 activity assisting in promoting DLBCL cell death and preventing resistance to targeted therapies. This evidence concerns the gene FOXO1 and diffuse large B-cell lymphoma.